Navigation Links
Decorated Trial Attorney Conard Metcalf Joins Simmons Firm as 'Of Counsel'

EAST ALTON, Ill., Aug. 24 /PRNewswire/ -- The Simmons firm, a leading national law firm in the fight against mesothelioma and other asbestos-related diseases, announced today that Conard Metcalf, one of the foremost trial attorneys in the country, has joined the firm as "Of Counsel."

Metcalf has tried dozens of asbestos cancer cases since the late 1970s. He has successfully represented many men and women diagnosed with mesothelioma and other asbestos-related diseases, including asbestosis, as well as other occupational diseases and toxic injuries.

"The Simmons firm is very fortunate to retain Mr. Metcalf's 'Of Counsel' services," Chairman and CEO John Simmons said. "Mr. Metcalf is widely respected in both the plaintiff's and defense bar for his knowledge of asbestos-related medicine and literature. We look forward to working with Mr. Metcalf, who will be an invaluable resource as we continue to commit ourselves to the needs of our clients inside and outside the courtroom."

Metcalf has been practicing law for more than 30 years. He received his law degree from the University of Colorado in 1972, where he was a member of the Law Review. In 1973, he received a Masters of Law degree from Columbia University in New York City. Today he is frequently sought after as a speaker about asbestos-related diseases at medical conferences and legal seminars around the country.

Mesothelioma, a rare cancer caused by exposure to asbestos, and other asbestos-related diseases kill approximately 10,000 people each year. Since 1999, the Simmons firm has helped thousands of families from every state in the country, including obtaining a $250 million verdict on behalf of a U.S. steel worker - the single largest asbestos verdict in the United States.

"The Simmons firm began with a focus to provide representation to victims suffering from what were and are preventable, life-ending illnesses," Metcalf said. "I'm pleased to join the firm as it celebrates its 10th anniversary. The Simmons firm has accomplished much for thousands of clients and has been a champion in fundraising and research. But much work remains."

The Simmons firm also is a leading national advocate in raising public awareness and funds for research to find better care, and, ultimately, a cure, for mesothelioma. The firm has pledged more than $20 million to charitable causes, including $15 million to cancer research, $10 million of which helped build the SimmonsCooper Cancer Institute at Southern Illinois University in Springfield.

"We will continue to fight for the rights of victims of asbestos-related diseases and their families," said Managing Partner Michael Angelides. "And we're happy to call Mr. Metcalf our colleague in this endeavor."

Metcalf has published articles about occupational diseases in several legal journals and belongs to a number of organizations, including the International Society of Barristers, which invites lawyers with demonstrated expertise as trial lawyers to be members. He is a founding member of Trial Lawyers for Public Justice, a national organization of trial lawyers representing people whose causes involve important issues of justice and fairness. Metcalf also wrote the brief on behalf of the Association of Trial Lawyers of America that was filed in the United States Supreme Court in the important asbestos case of Edwards v. Celotex.

About Simmons Browder Gianaris Angelides & Barnerd LLC

The Simmons firm is a leading national law firm in the fight against mesothelioma. With offices in Illinois and California, the firm has represented thousands of patients and families affected by mesothelioma from all across the country. The Simmons firm is passionate about improving the lives of victims of mesothelioma and asbestos-related illnesses and has pledged over $15 million to cancer research. The firm also has practice areas in intellectual property, pharmaceutical litigation, and business litigation.

SOURCE Simmons Browder Gianaris Angelides & Barnerd LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. TrinityCare Appoints Decorated Christian Artist Al Denson to Board of Directors
2. Bioniche Phase III Clinical Trial with Urocidin(TM) Given Continued Green Light by DMC
3. Swine Flu Vaccine Seems Safe in Early Trials
4. CRF announces featured clinical trials to be presented at TCT 2009 in San Francisco
5. DIA 3rd Annual Clinical Trial Disclosure Workshop Offers Strategies for Creating Effective Registries and Results Databanks
6. Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C
7. Detecting bias in the reporting of clinical trials
8. Hard To Treat Diseases (HTDS.PK) H1N1 Swine Flu Clinical Trial
9. Exsulin Corporation Announces Publication of Phase 2 Trial Results for Novel Islet Regeneration Treatment in Type 1 & Type 2 Diabetes
10. Light Sciences Oncology Expands Development of Novel Targeted Drug Aptocine(TM) For Prostate Conditions With Start-Up of Phase 2 BPH Trial
11. Oxygen Biotherapeutics, Inc. to Begin Oxycyte(R) Phase II Clinical Trials in Switzerland
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... ... aggressive than those found on mammography, according to a study published online in ... cancers not seen on mammography may necessitate a change in treatment. , Breast ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... offering factory direct sauna parts and accessories. , Sauna accessories help improve the ... bather’s style and personality. From basic styles for the purist looking for simplicity ...
(Date:11/25/2015)... ... November 25, 2015 , ... According to an article ... being more and more widely heralded as a breakthrough for performing hernia repairs. The ... over traditional laparoscopic surgery is that it can greatly reduce the pain that a ...
(Date:11/25/2015)... ... 25, 2015 , ... The McHenry County law firm of Botto Gilbert ... Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the ... App (2d) 130884WC. , According to court documents, Adcock testified that on May 10, ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... decades of music, friendships, and learning in its 65th Anniversary Brillianteen Revue, scheduled ... 5-6. , For 65 years, Brillianteen has been a treasured tradition ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Therapeutic Drug Monitoring (TDM) Market: Supplier ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/26/2015)... 2015 ) ... "Radioimmunoassay Market by Type (Reagents & Kits, ... Clinical Diagnostic Labs), Application (Research, Clinical Diagnostics), ... report to their offering. --> ... of the "Radioimmunoassay Market by Type ...
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
Breaking Medicine Technology: